CTMX CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platfo…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations. | ||
 CytomX Therapeutics Q2 Earnings Call Highlights CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv | ||
 CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||